Gefitinib in the Treatment of Advanced, Refractory Non–Small-Cell Lung Cancer: Results in 124 Patients

Jemal, 2003, Cancer statistics, 2003, CA Cancer J Clin, 53, 5, 10.3322/canjclin.53.1.5 Ginsberg, 2001, Non-small cell lung cancer, 925 Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954 Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095 Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354 Coiffier, 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma, N Engl J Med, 346, 235, 10.1056/NEJMoa011795 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against Her-2 for metastatic breast cancer that overexpresses Her- 2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Savage, 2002, Imatinib mesylate-a new oral targeted therapy, N Engl J Med, 346, 683, 10.1056/NEJMra013339 Rusch, 1993, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancer and adjacent benign lung, Cancer Res, 53, 2379 Tateishi, 1994, Prognositc influence of the co-expression of epidermal growth factor receptor and c-erB-2 protein in human lung adenocarcinoma, Surg Oncol, 3, 109, 10.1016/0960-7404(94)90006-X Fry, 2000, Site-directed irreversible inhibitors of the Erb-B family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer, Anticancer Drug Res, 15, 3 Ranson, 2002, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial, J Clin Oncol, 20, 2240, 10.1200/JCO.2002.10.112 Herbst, 2002, Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial, J Clin Oncol, 20, 3815, 10.1200/JCO.2002.03.038 Kris, 2002, A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2), Proc Am Soc Clin Oncol, 21, 292a Fukuoka, 2002, Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1), Proc Am Soc Clin Oncol, 21, 298a Kaplan, 1958, Non-parametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Kelly, 2001, Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial, J Clin Oncol, 19, 3210, 10.1200/JCO.2001.19.13.3210 Scagliotti, 2002, Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer, J Clin Oncol, 20, 4285, 10.1200/JCO.2002.02.068 Non-small cell lung cancer Collaborative Group, 1995, Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials, BMJ, 311, 899, 10.1136/bmj.311.7010.899 Kris, 2000, Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR), Lung Cancer, 29, 72, 10.1016/S0169-5002(00)80233-0 Perez-Soler, 2001, A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients with advanced, EGFR-expressing, nonsmall cell lung cancer, Proc Am Soc Clin Oncol, 20, 310a Douillard, 2002, Improvement in disease-related symptoms and quality of life in patients with advanced non-small cell lung cancer (NSCLC) treated with ZD1839 (Iressa) (IDEAL 1), Proc Am Soc Clin Oncol, 21, 299a Natale, 2002, Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD1839 (Iressa) in IDEAL-2, Proc Am Soc Clin Oncol, 21, 292a Cella, 1995, Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument, Lung Cancer, 12, 199, 10.1016/0169-5002(95)00450-F Ruckdeschel, 2002, ZD1839 (Iressa) as a single agent for the treatment of metastatic non-small cell lung cancer, Proc Am Soc Clin Oncol, 21, 318a Liem, 2002, Expanded access single institution clinical program experience with ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 21, 222b Soto Parra, 2002, ZD1839 (Iressa) in progressive pretreated non-small cell lung cancer (NSCLC): results from compassionate rise in patients at The Instituto Clinico Humanitas, Rozzano, Milano, Proc Am Soc Clin Oncol, 21, 210b Janne, 2002, ZD1839 (Iressa) shows antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol, Proc Am Soc Clin Oncol, 21, 319a Johnson DH, Herbst R, Giaccone G, et al. ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced nonsmall cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Abstracts from the 27th Congress of the European Society for Medical Oncology; Oct. 18-22, 2002; Nice, France (Abstract #468).